Skip to contentX
Xenon Pharmaceuticals Inc.
X
XENEXenon Pharmaceuticals Inc. Q1 2026 · 10-Q
Revenue$0.00$0.00−100.0% vs Q1 2025 Net Income-$102.30M-$102.30MN/M vs Q1 2025 EPS Diluted-$1.17-$1.17N/M vs Q1 2025 Operating Income-$112,328,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
Free Cash Flowderived-$89,030,000N/M ended Mar 31, 2026 · filed May 7, 2026 · 37 d after period end